Berberine vs CJC-1295 with DAC
Moderate Research vs Well Studied
synergistic Mechanism-based · 51% Berberine helps counteract the insulin-disrupting effects of CJC-1295 with DAC. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Berberine CJC-1295 with DAC
Weight 336.36 Da 3,647.28 Da
Half-life ~4 hours 6-8 days
Chain — 30 amino acids
Type Isoquinoline alkaloid (C20H18NO4+) GHRH analog with DAC
Key Benefits
Berberine
01 Activation of AMPK, improving cellular energy metabolism and glucose utilization
02 Clinically demonstrated reductions in fasting blood glucose and HbA1c comparable to metformin in some trials
03 Improved lipid profiles with reductions in total cholesterol, LDL cholesterol, and triglycerides
04 Enhanced insulin sensitivity through upregulation of insulin receptor expression
05 PCSK9 inhibition leading to improved LDL cholesterol clearance
06 Gut microbiome modulation favoring beneficial short-chain fatty acid-producing bacteria
07 Anti-inflammatory effects via NF-kB pathway suppression
08 Available over the counter as a dietary supplement without prescription
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Dosing Protocols
Berberine
500 mg 2-3x/day / 2-3x daily with meals
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Side Effects
Berberine
Gastrointestinal distress (diarrhea, cramping, bloating, nausea, flatulence) - most frequent complaint, affecting 10-15% of users, especially at higher doses or without food
Constipation (less common than diarrhea but reported by some users)
Decreased appetite
Mild abdominal discomfort, particularly during the first 1-2 weeks of use
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Contraindications
Pregnancy and breastfeeding (berberine may stimulate uterine contractions and crosses into breast milk)
Neonates and young children (risk of kernicterus - berberine can displace bilirubin from albumin)
Severe hepatic impairment
Concurrent use with medications that have narrow therapeutic indices metabolized by CYP3A4 (e.g., cyclosporine, tacrolimus) without close medical supervision
Known hypersensitivity to berberine or berberine-containing plants
Diabetes history
Cancer history
Predisposed sleep apnea
Research Evidence
Berberine CJC-1295 with DAC
Status Moderate Research Well Studied
References 5 studies 4 studies
Latest 2023 2025
FDA Approved No No
Full Berberine profile Full CJC-1295 with DAC profile Berberine calculator CJC-1295 with DAC calculator
More comparisons: MK-677
This comparison is for educational and research purposes only. Consult a healthcare professional before use.